Cadila has a carefully laid down business philosophy that ensures the effectiveness of our corporate governance policy which ensures absolute transparency and authenticity. Our policies fulfill the statutory obligations and accountability to the shareholders and running our operations with their active collaboration. Our well-established Corporate Governance Guidelines that are strictly followed in letter and spirit.
It's our responsibility to keep our work environment open, safe and empowering for everyone. Our policies support, protect you and the wider community, and enable you to create the change you want to see.
Cadila Pharmaceuticals Limited (“the Company” or “Company” or “CPL”) believes that Corporate Social Responsibility (CSR) is our commitment towards inclusive and sustainable growth. As a responsible Corporate Citizen, CPL undertakes a number of CSR activities in larger interest of the community, especially in the area of health, education, women empowerment, and childcare and environment protection.
Principles of corporate governance require Independent Directors to review the overall strategy, oversee the performance of management and participate and arrive at an independent judgment.
Compliance policy lays the framework of the committee that initiates the investigation of the fraud/misconduct/ dishonest behavior within two business days.
The objective of the risk management policy is to ensure that the company has proper and continuous risk identification and management process.
This Code of Conduct is evidence of our commitment towards our employees and being an employer of choice. We are an equal opportunity employer and condemn any form of harassment and discrimination in the workplace.
This Whistle Blower Policy has been formulated to enable all stakeholders including employees and directors to raise concern against any malpractice and potential infractions of the Code of Conduct of the Company, breaches of copyright or patent and alike.
The primary function of the NRC is to govern the appointment, remuneration and evaluation of performance of directors (including independent directors), Key Managerial Personnel and other Senior Management of the Company.
Annual Return pursuant to Section 92(3) of the Companies Act, 2013.
For any grievances, please send your concerns to the following contact – Mr. Kinjal Choudhary – Global President HR – Cadila Pharmaceuticals at email id – firstname.lastname@example.org